PRESS RELEASE published on 01/04/2024 at 12:30, 2 years 8 months ago NanoViricides to Present at the Biotech Showcase in San Fransisco NanoViricides, Inc., a leader in antiviral therapies based on nanomedicines technology, is set to present at the Biotech Showcase™ 2024 in San Francisco. The presentation will include an update on the successful Phase 1 clinical trials of NV-CoV-2 Oral Syrup and Oral Gummies, which contain the novel antiviral nanomachine NV-387. The company's President will discuss how NV-387 addresses the unmet need for a broad-spectrum antiviral drug as well as its potential across multiple virus families. With its wide spectrum of antiviral activity, NV-387 has the potential to revolutionize antiviral treatment, much like antibiotics did for bacterial infections. NanoViricides Antiviral Therapies NV-387 Biotech Showcase 2024 Broad-spectrum Antiviral Drug
PRESS RELEASE published on 11/28/2023 at 12:40, 2 years 10 months ago The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
PRESS RELEASE published on 11/15/2023 at 12:45, 2 years 10 months ago NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
PRESS RELEASE published on 11/14/2023 at 12:45, 2 years 10 months ago Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
PRESS RELEASE published on 10/16/2023 at 12:45, 2 years 11 months ago NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
PRESS RELEASE published on 10/12/2023 at 12:45, 2 years 11 months ago NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
PRESS RELEASE published on 08/21/2023 at 12:45, 3 years 1 month ago The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
PRESS RELEASE published on 07/11/2023 at 12:45, 3 years 2 months ago Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
PRESS RELEASE published on 07/06/2023 at 12:45, 3 years 2 months ago Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
PRESS RELEASE published on 06/29/2023 at 12:45, 3 years 2 months ago NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
Published on 09/29/2026 at 06:45, 9 minutes ago Akkodis and Biolevate Partner to Accelerate AI-Powered Scientific, Regulatory and Technical Documentation in Highly Regulated Industries
Published on 09/29/2026 at 04:36, 2 hours 18 minutes ago The Next Decade of Medical AI: How Humans and AI Collaborate - A Conversation Between Kevin Kelly and Dr. Ning Song of Diagens Tech (2526. HK)
Published on 09/29/2026 at 02:30, 4 hours 24 minutes ago QNX and neueHCT Join Forces to Accelerate Global Intelligent Driving Deployment, Anchored by Major German Automaker Program Win
Published on 09/29/2026 at 00:00, 6 hours 54 minutes ago Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical Trial
Published on 09/28/2026 at 23:00, 7 hours 54 minutes ago CORRECTION FROM SOURCE: Organto Foods Highlights Record First Half Results and Progress on Key Strategic Initiatives
Published on 09/29/2026 at 06:46, 8 minutes ago Julius Baer confirms conclusion of FINMA enforcement procedure in legacy matters
Published on 09/29/2026 at 06:12, 42 minutes ago EQS-Adhoc: Marley Spoon Group SE: Marley Spoon Group SE announces global workforce reductions
Published on 09/29/2026 at 05:35, 1 hour 19 minutes ago Castrol launches 'Castrol CORE', an integrated thermal management offer for data centres
Published on 09/28/2026 at 22:14, 8 hours 40 minutes ago EQS-Adhoc: Extension of the Managing Directors' employment contracts of Carsten Cramer, Lars Ricken and Thomas Treß – Carsten Cramer appointed Chairman of the Management Board
Published on 09/28/2026 at 17:54, 12 hours 59 minutes ago Reporting on share buyback transactions carried out between September 21 and September 25, 2026
Published on 09/28/2026 at 17:54, 12 hours 59 minutes ago Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain entre le 21 et le 25 septembre 2026
Published on 09/28/2026 at 17:45, 13 hours 9 minutes ago Déclaration hebdomadaire de rachat d'actions
Published on 09/28/2026 at 17:35, 13 hours 19 minutes ago Déclaration hebdomadaire d'opérations effectuées du 21 au 25 septembre 2026
